Last reviewed · How we verify
DTaP IPV HB PRP~T vaccine — Competitive Intelligence Brief
phase 3
vaccine
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
DTaP IPV HB PRP~T vaccine (DTaP IPV HB PRP~T vaccine) — Sanofi Pasteur, a Sanofi Company. This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DTaP IPV HB PRP~T vaccine TARGET | DTaP IPV HB PRP~T vaccine | Sanofi Pasteur, a Sanofi Company | phase 3 | vaccine | ||
| Comirnaty | BNT162b2 (tozinameran) | Pfizer Inc. | marketed | vaccine | SARS-CoV-2 virus | 2021-08-23 |
| Prevnar 20 | pneumococcal 20-valent conjugate vaccine (PCV20) | Pfizer Inc. | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (20 serotypes) | 2021-06-08 |
| Vaccine Support Cp | Vaccine administration | Women and Infants Hospital of Rhode Island | marketed | vaccine | unknown | |
| TT | TT | CanSino Biologics Inc. | marketed | Viral vector vaccine | SARS-CoV-2 spike protein | |
| RSV prefusion F protein-based vaccine | rsv-prefusion-f-protein-based-vaccine | Pfizer Inc. | marketed | Viral protein subunit vaccine | Respiratory syncytial virus fusion (F) protein | |
| Tozinameran 12 Years of age and older | tozinameran-12-years-of-age-and-older | Pfizer | marketed | vaccine | SARS-CoV-2 spike protein |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Prevnar 20 · US 8,895,024 · Composition of matter · US
- — Prevnar 20 · US 10,279,033 · Method of use · US
Sponsor landscape (vaccine class)
- Pfizer · 20 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
- GlaxoSmithKline · 12 drugs in this class
- Merck Sharp & Dohme LLC · 12 drugs in this class
- Centers for Disease Control and Prevention · 9 drugs in this class
- Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
- Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
- Beijing Center for Disease Control and Prevention · 6 drugs in this class
- International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
- Sinovac Biotech Co., Ltd · 4 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DTaP IPV HB PRP~T vaccine CI watch — RSS
- DTaP IPV HB PRP~T vaccine CI watch — Atom
- DTaP IPV HB PRP~T vaccine CI watch — JSON
- DTaP IPV HB PRP~T vaccine alone — RSS
- Whole vaccine class — RSS
Cite this brief
Drug Landscape (2026). DTaP IPV HB PRP~T vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/dtap-ipv-hb-prp-t-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab